Investors

Webcast ImageClick here for Webcast
Q2 2016 Xtant Medical Holdings Inc Earnings Conference Call (Live)
08/02/16 at 10:00 a.m. ET
Q2 2016 Xtant Medical Holdings Inc Earnings Conference Call
Tuesday, August 2, 2016 10:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and...
More

Stock Quote
XTNT (Common Stock)
Price$1.80
Change (%) + 0.03 (1.69%)
Volume4,804
Data as of 07/29/16 3:48 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: XTNT.K.  Currently trading at $1.80 with a 52 week high of $4.49 and a 52 week low of $1.51.
Recent News
DateTitle 
07/26/16Xtant™ Medical Announces the Operations Expansion of Montana’s Tissue Processing Rooms
BELGRADE, Mont., July 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the expansion of its tissue processing facility in Belgrade, MT, which now includes an additional seven new processing rooms. This more than doubles the capacity of processing rooms available for production. The new processing suite will improve both production efficiency and utilization of resourc... 
07/20/16Xtant™ Medical Pre-Announces Second Quarter 2016 Revenue and EBITDA
Second Quarter 2016 Revenue in the range of $21.45 million to $21.65 million Core recurring revenue to increase 5.6% to 6.6% over the same period last year EBITDA projected to be $300,000-$400,000 for Second Quarter 2016 BELGRADE, Mont., July 20, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, has preannounced that its second quarter 2016 revenue is expected to be in the range of $21.... 
07/19/16Xtant Medical Holdings, Inc. to Report Second Quarter 2016 Financial Results on August 1, 2016
BELGRADE, Mont., July 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the period ended June 30th 2016, at the close of the financial markets on August 1, 2016. An accompanying conference call will be hosted by Dan Goldberger, Chief Executive Officer, and John Gandolfo, Chief Financial Officer, to discuss the results. The call ... 
06/16/16Xtant™ Medical Announces Changes to Its Executive Management and Board of Directors
BELGRADE, Mont., June 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman, Eric Timko, and Rudy Mazzocchi to its Board of Directors.  The Company also announced the resignation of Directors Jon Wickwire and David Goodman.  The above changes will be effective as of July 2, 2016. Paul Buckman has more than 30 years of experience as a busines... 
More

Upcoming Events
DateTitle
08/02/16 10:00 a.m. ET
Q2 2016 Xtant Medical Holdings Inc Earnings Conference Call
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.